Orchid Chemicals & Pharmaceuticals Ltd (Orchid) has received approvals of its Marketing Authorization (MA) for Piperacillin and Tazobactam for Injection for marketing in the EU countries

Orchid filed the MA for this product with the UK MHRA through the DCP (de-centralised procedure) route enabling the company to launch the product across EU countries. Product will be soon launched through Hospira.

“This is a very important milestone in our regulated generics plan. Through this approval, we are expanding into a new product range of premium Penicillin Injectables and also foraying into the EU generics market. We are launching this product through our exclusive marketing alliance with Hospira for the EU market and given the limited competition envisaged in this product we are confident of a robust market share and revenue stream”, said Mr K Raghavendra Rao, Managing Director, Orchid Chemicals & Pharmaceuticals Ltd.